Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety Efficacy of ABT-874 to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Briakinumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories
- 06 Oct 2017 Results (n=273) of a post hoc retrospective analysis developing and validating a prediction rule to identify patients unlikely to respond adequately to methotrexate using patient data from NCT00235820 and NCT00679731 trials published in the Journal of the American Academy of Dermatology
- 08 Mar 2016 Results (n=849) of a pooled subgroup analysis from this and two other trials (see profile 40201 and 255049) presented at the 74th Annual Meeting of the American Academy of Dermatology
- 08 Mar 2016 Results (pooled subgroup analysis of this and other 3 phase III studies, n = 1558) presented at the 74th Annual Meeting of the American Academy of Dermatology.